CAPRICOR THERAPEUTICS, INC.
For the period ended Dec 31, 2025. Filed Mar 17, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 17, 2026
CAPR$8.87-9.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
CONSOLIDATED STATEMENTS OF CASH FLOWS
FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024
| | | | | | | |
|---|---|---|---|---|---|---|
| · · Years ended December 31, | ||||||
| · · 2025 · · 2024 | ||||||
| Cash flows from operating activities: | | | | | | |
| Net loss | | $(105,043,946) | | $(40,467,186) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | | | | | ||
| Loss on disposal of fixed assets | | | 157,519 | | | 112,805 |
| Depreciation and amortization | | 1,889,041 | | 1,425,214 | ||
| Stock-based compensation | | 16,967,799 | | 9,765,164 | ||
| Restricted stock awards granted | | | 257,461 | | | — |
| Changes in lease liabilities | | | 715,459 | | | (47,261) |
| Non-cash interest expense on CIRM liability | | | 3,045,725 | | | — |
| Changes in operating assets and liabilities: | | | | | ||
| Receivables | | 10,309,322 | | 3,504 | ||
| Prepaid expenses and other assets | | (4,093,633) | | (458,653) | ||
| Accounts payable and accrued expenses | | | 5,983,992 | | | 1,941,136 |
| Deferred revenue | | — | | (12,270,465) | ||
| Net cash used in operating activities | | (69,811,261) | | (39,995,742) | ||
| | | | | | | |
| Cash flows from investing activities: | | | | | ||
| Purchase of marketable securities | | (151,392,398) | | (208,441,162) | ||
| Proceeds from sales and maturities of marketable securities | | 260,595,875 | | 93,796,269 | ||
| Purchases of property and equipment | | | (2,904,461) | | | (1,166,871) |
| Payments for leasehold improvements | | (383,539) | | (372,104) | ||
| Payments for construction in progress | | | (8,436,196) | | | — |
| Net cash provided by (used in) investing activities | | 97,479,281 | | (116,183,868) | ||
| | | | | | | |
| Cash flows from financing activities: | | | | | ||
| Net proceeds from sale of common stock | | 237,033,938 | | 152,321,576 | ||
| Proceeds from exercise of stock awards and warrants | | 11,858,358 | | 450,173 | ||
| Net cash provided by financing activities | | 248,892,296 | | 152,771,749 | ||
| | | | | | | |
| Net increase (decrease) in cash and cash equivalents | | 276,560,316 | | (3,407,861) | ||
| | | | | | | |
| Cash and cash equivalents balance at beginning of period | | 11,286,996 | | 14,694,857 | ||
| | | | | | | |
| Cash and cash equivalents balance at end of period | | $287,847,312 | | $11,286,996 | ||
| | | | | | | |
| Supplemental disclosures of cash flow information: | | | | | ||
| Interest paid in cash | | $— | | $— | ||
| Income taxes paid in cash | | $1,600 | | $1,600 | ||
| Initial recognition of right-of-use asset | | $13,382,191 | | $— | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.